MX2018006445A - Oligonucleotidos antisentido de interleucina-34 (il-34) y metodos de uso de los mismos. - Google Patents
Oligonucleotidos antisentido de interleucina-34 (il-34) y metodos de uso de los mismos.Info
- Publication number
- MX2018006445A MX2018006445A MX2018006445A MX2018006445A MX2018006445A MX 2018006445 A MX2018006445 A MX 2018006445A MX 2018006445 A MX2018006445 A MX 2018006445A MX 2018006445 A MX2018006445 A MX 2018006445A MX 2018006445 A MX2018006445 A MX 2018006445A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- fibrosis
- disclosed
- same
- antisense oligonucleotide
- Prior art date
Links
- 239000000074 antisense oligonucleotide Substances 0.000 title abstract 4
- 238000012230 antisense oligonucleotides Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 abstract 3
- 230000004761 fibrosis Effects 0.000 abstract 3
- 208000027866 inflammatory disease Diseases 0.000 abstract 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260076P | 2015-11-25 | 2015-11-25 | |
| PCT/EP2016/078833 WO2017089555A1 (en) | 2015-11-25 | 2016-11-25 | Il-34 antisense oligonucleotides and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018006445A true MX2018006445A (es) | 2018-08-01 |
Family
ID=57471829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018006445A MX2018006445A (es) | 2015-11-25 | 2016-11-25 | Oligonucleotidos antisentido de interleucina-34 (il-34) y metodos de uso de los mismos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180338992A1 (https=) |
| EP (1) | EP3380615B1 (https=) |
| JP (2) | JP2018535681A (https=) |
| KR (1) | KR20180084956A (https=) |
| CN (1) | CN108473989A (https=) |
| AU (1) | AU2016360956A1 (https=) |
| BR (1) | BR112018010736A2 (https=) |
| CA (1) | CA3005932A1 (https=) |
| ES (1) | ES2861516T3 (https=) |
| MA (1) | MA44309A (https=) |
| MX (1) | MX2018006445A (https=) |
| PT (1) | PT3380615T (https=) |
| WO (1) | WO2017089555A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3420082A4 (en) * | 2016-02-23 | 2019-10-16 | Celgene Alpine Investment Company II, LLC | METHOD FOR THE TREATMENT OF DARM FIBROSIS USING SMAD7 INHIBITION |
| AU2020384935A1 (en) * | 2019-11-15 | 2022-06-09 | Nogra Pharma Limited | IL-34 antisense agents and methods of using same |
| AU2022276078A1 (en) | 2021-05-17 | 2024-01-04 | Nogra Pharma Limited | Il-34 antisense agents and methods of using same |
| WO2022243299A1 (en) * | 2021-05-17 | 2022-11-24 | Nogra Pharma Limited | Il-34 antisense agents and methods of using same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| EP2242854A4 (en) * | 2008-01-15 | 2012-08-15 | Quark Pharmaceuticals Inc | COMPOUNDS AND USES THEREOF |
| RU2593939C2 (ru) | 2008-11-13 | 2016-08-10 | Ногра Фарма Лимитед | Антисмысловые композиции и способы их получения и применения |
| GB0910833D0 (en) * | 2009-06-23 | 2009-08-05 | Univ Edinburgh | Avian genes |
| US20130028889A1 (en) * | 2010-02-04 | 2013-01-31 | Ico Therapeutics Inc. | Dosing regimens for treating and preventing ocular disorders using c-raf antisense |
| AR080698A1 (es) * | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| DK2734547T3 (en) * | 2011-07-18 | 2017-04-03 | Univ Melbourne | USE OF C-FMS ANTIBODIES |
| CN107759690A (zh) * | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| GB201315486D0 (en) * | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| KR20150104275A (ko) * | 2014-03-05 | 2015-09-15 | 울산대학교 산학협력단 | 비만 관련 질환의 진단과 치료를 위한 il-34의 용도 |
| CA2954791C (en) * | 2014-07-14 | 2025-11-18 | The Regents Of The University Of California | CRISPR/CAS TRANSCRIPTIONAL MODULATION |
-
2016
- 2016-11-25 PT PT168053510T patent/PT3380615T/pt unknown
- 2016-11-25 MA MA044309A patent/MA44309A/fr unknown
- 2016-11-25 CA CA3005932A patent/CA3005932A1/en not_active Abandoned
- 2016-11-25 KR KR1020187017448A patent/KR20180084956A/ko not_active Withdrawn
- 2016-11-25 EP EP16805351.0A patent/EP3380615B1/en active Active
- 2016-11-25 JP JP2018526797A patent/JP2018535681A/ja active Pending
- 2016-11-25 MX MX2018006445A patent/MX2018006445A/es unknown
- 2016-11-25 AU AU2016360956A patent/AU2016360956A1/en not_active Abandoned
- 2016-11-25 CN CN201680077787.9A patent/CN108473989A/zh active Pending
- 2016-11-25 US US15/778,688 patent/US20180338992A1/en not_active Abandoned
- 2016-11-25 BR BR112018010736A patent/BR112018010736A2/pt not_active IP Right Cessation
- 2016-11-25 WO PCT/EP2016/078833 patent/WO2017089555A1/en not_active Ceased
- 2016-11-25 ES ES16805351T patent/ES2861516T3/es active Active
-
2021
- 2021-05-06 JP JP2021078549A patent/JP2021106625A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3005932A1 (en) | 2017-06-01 |
| EP3380615A1 (en) | 2018-10-03 |
| AU2016360956A1 (en) | 2018-06-07 |
| MA44309A (fr) | 2018-10-03 |
| ES2861516T3 (es) | 2021-10-06 |
| PT3380615T (pt) | 2021-04-01 |
| KR20180084956A (ko) | 2018-07-25 |
| JP2021106625A (ja) | 2021-07-29 |
| EP3380615B1 (en) | 2021-01-06 |
| JP2018535681A (ja) | 2018-12-06 |
| BR112018010736A2 (pt) | 2018-11-27 |
| CN108473989A (zh) | 2018-08-31 |
| WO2017089555A1 (en) | 2017-06-01 |
| US20180338992A1 (en) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284423A (en) | Antisense oligonucleotides for the treatment of Pompe disease | |
| NZ730296A (en) | Modified double-stranded rna agents | |
| PH12018500719A1 (en) | Oligonucleotide compositions and methods thereof | |
| PH12018500586B1 (en) | Farnesoid x receptor agonists and uses thereof | |
| PH12017501956A1 (en) | Compositions of obeticholic acid and methods of use | |
| MX2022016376A (es) | Oligonucleotidos para inducir la expresion paterna de la ligasa de la proteina ubiquitina e3a (ube3a). | |
| PH12017500424A1 (en) | Mir-29 mimics and uses thereof | |
| WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
| UA117098C2 (uk) | Сполука, що містить модифікований олігонуклеотид | |
| MX2016001587A (es) | Inhibidores de kdm1a para el tratamiento de enfermedades. | |
| MX359548B (es) | Agentes de iarn modificados. | |
| MX381121B (es) | Supresión del gen de la huntingtina inducida por la arni | |
| MX2015011943A (es) | Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados. | |
| MX2017002816A (es) | Derivados de pirazolopiridina y su uso en terapia. | |
| EP3128008C0 (en) | DOUBLE-STRANDED OLIG-RNA AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR THE PREVENTION OR TREATMENT OF FIBROSIS OR RESPIRATORY DISEASES | |
| PH12016500863A1 (en) | Tetracyclic autotaxin inhibitors | |
| MX2017001293A (es) | Metodos y composiciones para diagnosticar y tratar trastornos inflamatorios del intestino. | |
| HK1252852A1 (zh) | 阻止HIF2α基因表达的组合物及方法 | |
| TW201613949A (en) | Targeting microRNAs for metabolic disorders | |
| MX2018006445A (es) | Oligonucleotidos antisentido de interleucina-34 (il-34) y metodos de uso de los mismos. | |
| GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
| MX2018005872A (es) | Profarmacos de acido nucleico. | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| TN2018000122A1 (en) | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | |
| MX2022005900A (es) | Agentes antisentido de il-34 y metodos de uso de los mismos. |